Related Experiment Video

Updated: Mar 17, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K

[Metformin impact on purine metabolism in breast cancer]

O P Shatova1, Eu V Butenko1, Eu V Khomutov1

  • 1Gorky Donetsk National Medical University, Donetsk, Ukraine.

Biomeditsinskaia Khimiia
|July 16, 2016
PubMed

Insights

Metformin alters purine metabolism in breast cancer, increasing adenosine deaminase activity. However, this change does not reduce tumor adenosine levels, suggesting complex effects on adenosinergic immunosuppression.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Metformin is widely used in oncology, but its anti-tumor mechanisms require further elucidation.
  • Understanding metformin's impact on the tumor microenvironment is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To investigate metformin's effect on adenosine deaminase activity and adenosinergic immunosuppression in breast cancer.
  • To analyze purine metabolite changes in breast adenocarcinoma tissue related to metformin use.

Main Methods:

  • Analysis of breast cancer tissue from patients receiving metformin versus those not on the drug.
  • High-Performance Liquid Chromatography (HPLC) was used to quantify adenosine, inosine, hypoxanthine, and adenosine deaminase activity.

Main Results:

  • Metformin significantly alters purine nucleotide catabolism in breast adenocarcinoma tissue.
  • Increased adenosine deaminase activity due to metformin was insufficient to lower adenosine levels in cancer tissue.
  • Patients on metformin showed unchanged adenosine concentrations but significantly increased inosine and hypoxanthine levels.

Conclusions:

  • Metformin impacts purine metabolism in breast cancer, affecting adenosine deaminase activity and its products.
  • The observed changes suggest a complex interplay between metformin, purine metabolism, and the tumor microenvironment's immunosuppressive potential.
Keywords:
adenosineadenosine deaminasebreast cancerhypoxanthineinosinemetformin

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
351
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
267
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K